1636. Risk of Latent Tuberculosis Reactivation in Patients Treated with Checkpoint Inhibitors Immunotherapy Compared to Other Anti-Cancer Therapies including Hematopoietic Cell Transplantation

BACKGROUND: The risk of latent tuberculosis infection (LTBI) reactivation in cancer patients during checkpoint inhibitor immunotherapy (CPI) remains largely unknown. We sought to evaluate LTBI therapy and outcomes between cancer patients receiving CPI versus conventional chemotherapy (CC) and hemato...

Descripción completa

Detalles Bibliográficos
Autores principales: Malek, Alexandre, Chaftari, Patrick, dagher, Hiba, Hachem, Ray Y, Chaftari, Anne-Marie, Viola, George, Raad, Issam I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777861/
http://dx.doi.org/10.1093/ofid/ofaa439.1816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777861/
http://dx.doi.org/10.1093/ofid/ofaa439.1816

Ejemplares similares